This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing In PolyMedix, Inc. To Contact The Firm





NEW YORK, July 13, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at PolyMedix, Inc. ("PolyMedix" or the "Company") (OTC BB: PYMX).

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO )

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that:  (1) the Company's experimental compounds caused hypotension more often and at lower doses than acknowledged; (2) varying doses of the compound would not eliminate its adverse side effects on a patient's blood pressure; and (3) as a result, the development of the Company's drug pipeline and business prospects were at significant risk.

On March 7, 2011, the Company, along with its Chief Executive Officer, Chief Financial Officer and Vice President of Cardiovascular Clinical Development, issued a series of materially false and misleading statements to investors concerning the commercial viability, safety and market potential of the Company's experimental drug, PMX-60056, which caused Company shares to trade at artificially inflated prices.

On May 10, 2012, PolyMedix issued a press release disclosing to investors that the Company was halting patient enrollment in clinical trials for PMX-60056 "due to observations of reductions in blood pressure."  When the true state of PMX-60056's clinical development and adverse side effects became public, shares of PolyMedix's common stock declined a staggering 29%, closing on May 11, 2012 at $0.36 per share.

Request more information now by clicking here:  www.faruqilaw.com/PYMX. There is no cost or obligation to you.

Take ActionIf you purchased PolyMedix securities between March 7, 2011 and May 10, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/PYMX.  You can also contact us by calling Juan Monteverde, Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to jmonteverde@faruqilaw.com, rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding PolyMedix's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.FARUQI & FARUQI, LLP369 Lexington Avenue, 10th Floor New York, NY 10017Attn:  Juan Monteverde, Esq. jmonteverde@faruqilaw.com Richard Gonnello, Esq. rgonnello@faruqilaw.com Francis McConville, Esq. fmcconville@faruqilaw.comTelephone: (877) 247-4292 or (212) 983-9330

SOURCE Faruqi & Faruqi, LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs